We bring you the latest news from the healthcare about the health care in the United Kingdom.

dinsdag 5 september 2017

The Lancet: [News] Androgen deprivation therapy for prostate cancer

[News] Androgen deprivation therapy for prostate cancer
Androgen deprivation therapy (ADT) for localised prostate cancer is associated with an increased risk of cardiac failure and other cardiac dysfunction, a new study has found. However, another study of ADT in patients with prostate cancer has shown that ADT does not increase the risk of Alzheimer's disease.
Read more

[Comment] Defeating anaemia in myelodysplastic syndromes: another step forward
Myelodysplastic syndromes remain a group of neoplasias of difficult characterisation and even more difficult and frustrating clinical management, despite the increasing availability of treatment options. In The Lancet Oncology, Uwe Platzbecker and collegues1 have led a clinical study that has not only potentially opened new avenues for treatment of lower risk anaemic patients with myelodysplastic syndrome, but also has implications for the understanding of the biology of myelodysplastic syndrome.
Read more

[Comment] miR-16: expanding the range of molecular targets in mesothelioma
Malignant mesothelioma is a cancer caused by exposure to asbestos. It has a devastating prognosis, and its incidence has increased substantially in high-income countries during the past three decades. Systemic therapy comprising cisplatin and pemetrexed remains the only approved standard of care, a therapeutic plateau that has endured for more than 10 years. New, effective therapies based on an understanding of the underlying biology are clearly needed. By contrast with many other cancers, including lung cancer and melanoma, somatic mutations in oncogenic kinases have not been identified in the genomic landscape of mesotheliomas.
Read more

[Articles] Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
Luspatercept was well tolerated and effective for the treatment of anaemia in lower-risk myelodysplastic syndromes and so could therefore provide a novel therapeutic approach for the treatment of anaemia associated with lower-risk myelodysplastic syndromes; further studies are ongoing.
Read more

[Articles] Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Doxorubicin should remain the standard first-line treatment for most patients with advanced soft-tissue sarcoma. These results provide evidence for clinicians to consider with their patients when selecting first-line treatment for locally advanced or metastatic soft-tissue sarcoma.
Read more